多替阿巴拉米片漏服要怎么处理？

Dolutegravir tablets () are suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B*5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the RLA-B*5701 allele, he should not take products containing abacavir.

Domitabalamid Tablets (Simeika) are for use in adults and adolescents (weighing at least 40kg): For adults and adolescents, the recommended dose of Sumeika is one tablet, once daily. Adults or adolescents whose body weight is less than 40 kg should not be given Dolutea (Trimax) because Trimax is a fixed-dose tablet and cannot be reduced.

Trimecavir is a fixed-dose tablet and cannot be used in patients who require dose adjustments. If one of the active ingredients needs to be discontinued or dose adjusted, a separate formulation of dolutegravir, abacavir or lamivudine can be used. Abacavir is mainly metabolized by the liver. There are no clinical data in patients with moderate or severe hepatic impairment, therefore, use of Trimax is not recommended unless deemed necessary. For patients with mild hepatic impairment (Child-Pugh score 5-6), close monitoring is required, including monitoring of abacavir plasma levels.

What should I do if I miss taking Abalami Tablets?

If the patient misses a dose and there are more than 4 hours left before the next dose, he should take Doptabalamid Tablets (Suimeike) as soon as possible. If the next dose is less than 4 hours away, patients should not take the missed dose and simply resume their usual dosing schedule.

Recommended hot articles: /newsDetail/82194.html